Home LiteratureArticle Details
PMID: 21130159 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Neuroprotective strategies involving ROS in Alzheimer disease.

Free radical biology & medicine ·Vol. 51 ·No. 5 ·2011-09-01 ·Pages 1014-26

Dumont M, Beal MF

Abstract

Alzheimer disease (AD) is a neurodegenerative disorder in which oxidative stress is a key hallmark. It occurs early in disease pathogenesis and can exacerbate its progression. Several causes of oxidative stress have been determined over the years. First, mitochondria play an important role in the generation and accumulation of free radicals. In addition to mitochondria, inflammation can also induce oxidative damage, especially via microglia, and microglia are also important for Aβ clearance. In AD, both mitochondrial function and inflammatory response are affected, leading to increased ROS formation and oxidative damage to lipid, proteins, and nucleic acids. Some other sources have also been identified. From these findings, various neuroprotective strategies against ROS-mediated damages have been elaborated in AD research. This review recapitulates some of the major strategies used to prevent oxidative stress and disease progression. Outcomes from in vitro and in vivo studies using models of AD are encouraging. However, only a few clinical trials have provided positive results in terms of slowing down cognitive decline. Nonetheless, there is still hope for improved compounds that would better target pathways implicated in ROS production. In fact, facilitating the endogenous antioxidant system by modulating transcription has great promise for AD therapy.

MeSH Terms
Alzheimer Disease/drug therapy,metabolism,physiopathology Animals Antioxidants/pharmacology,therapeutic use Clinical Trials as Topic Disease Models, Animal Disease Progression Humans Inflammation Microglia/metabolism Mitochondria/metabolism Molecular Targeted Therapy/trends Neuroprotective Agents/pharmacology,therapeutic use Oxidation-Reduction Oxidative Stress/drug effects Reactive Oxygen Species/metabolism
Chemicals
Antioxidants Neuroprotective Agents Reactive Oxygen Species
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Dumont Magali
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY 10065, USA. mad2138@med.cornell.edu
Beal M Flint
References (184)
184 references, click to expand
  1. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model.
    Neurobiol Aging. 2011 Mar;32(3):398-406 PMID: 19362755
  2. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease.
    Ann Neurol. 1994 Nov;36(5):747-51 PMID: 7979220
  3. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients.
    J Alzheimers Dis. 2006 Sep;10(1):1-7 PMID: 16988474
  4. Biomarkers of oxidative damage and inflammation in Alzheimer's disease.
    Biomark Med. 2010 Feb;4(1):27-36 PMID: 20383271
  5. MitoQ--a mitochondria-targeted antioxidant.
    IDrugs. 2007 Jun;10(6):399-412 PMID: 17642004
  6. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.
    Mol Neurobiol. 2010 Jun;41(2-3):107-14 PMID: 20217279
  7. Oxidative RNA damage and neurodegeneration.
    Curr Med Chem. 2007;14(28):2968-75 PMID: 18220733
  8. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
    J Exp Med. 1996 Oct 1;184(4):1425-33 PMID: 8879214
  9. The role of microglia in amyloid clearance from the AD brain.
    J Neural Transm (Vienna). 2010 Aug;117(8):949-60 PMID: 20552234
  10. Novel drug targets based on metallobiology of Alzheimer's disease.
    Expert Opin Ther Targets. 2010 Nov;14(11):1177-97 PMID: 20942746
  11. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  12. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
    Aging Clin Exp Res. 2009 Apr;21(2):102-10 PMID: 19448381
  13. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation.
    J Mol Neurosci. 2008 Feb;34(2):165-71 PMID: 18181031
  14. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    N Engl J Med. 1997 Apr 24;336(17):1216-22 PMID: 9110909
  15. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe.
    Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E252-60 PMID: 14570702
  16. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease.
    J Alzheimers Dis. 2008 Jun;14(2):225-34 PMID: 18560133
  17. Coenzyme Q10 effects in neurodegenerative disease.
    Neuropsychiatr Dis Treat. 2009;5:597-610 PMID: 19966907
  18. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.
    Free Radic Biol Med. 2010 Jul 15;49(2):147-58 PMID: 20338236
  19. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model.
    J Clin Invest. 2008 Feb;118(2):659-70 PMID: 18219391
  20. Protective effect of curcumin against lead neurotoxicity in rat.
    Hum Exp Toxicol. 2003 Dec;22(12):653-8 PMID: 14992327
  21. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons.
    Bull Exp Biol Med. 2003 Nov;136(5):474-7 PMID: 14968164
  22. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54 PMID: 16446752
  23. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model.
    Biochem Biophys Res Commun. 2009 Feb 6;379(2):406-10 PMID: 19109927
  24. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
    Neurology. 2003 Dec 9;61(11):1498-502 PMID: 14663031
  25. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3.
    J Alzheimers Dis. 2004 Dec;6(6):659-71; discussion 673-81 PMID: 15665406
  26. Oxidative stress in Alzheimer disease: a possibility for prevention.
    Neuropharmacology. 2010 Sep-Oct;59(4-5):290-4 PMID: 20394761
  27. Assessment of antioxidant capacity in vitro and in vivo.
    Free Radic Biol Med. 2010 Aug 15;49(4):503-15 PMID: 20416370
  28. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease.
    J Neurol Sci. 2009 Aug 15;283(1-2):199-206 PMID: 19342064
  29. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
    JAMA. 2009 Dec 16;302(23):2557-64 PMID: 20009055
  30. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets.
    Antioxid Redox Signal. 2009 Oct;11(10):2535-52 PMID: 19309261
  31. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.
    Nat Med. 2008 Oct;14(10):1097-105 PMID: 18806802
  32. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lancet Neurol. 2008 Sep;7(9):779-86 PMID: 18672400
  33. NOX enzymes in the central nervous system: from signaling to disease.
    Antioxid Redox Signal. 2009 Oct;11(10):2481-504 PMID: 19309263
  34. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
    Neurology. 2000 Sep 26;55(6):805-10 PMID: 10994000
  35. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Pharmacopsychiatry. 2002 Jan;35(1):12-8 PMID: 11819153
  36. Pharmacological modulation of nitric oxide synthesis by mechanism-based inactivators and related inhibitors.
    Pharmacol Ther. 1999 Nov;84(2):157-78 PMID: 10596904
  37. Delaying the mitochondrial decay of aging with acetylcarnitine.
    Ann N Y Acad Sci. 2004 Nov;1033:108-16 PMID: 15591008
  38. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP.
    Free Radic Biol Med. 2010 Jan 1;48(1):136-44 PMID: 19854267
  39. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone.
    Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14342-7 PMID: 17766440
  40. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation.
    Brain Res. 2002 Oct 25;953(1-2):135-43 PMID: 12384247
  41. Acetyl-L-carnitine. Monograph.
    Altern Med Rev. 2010 Apr;15(1):76-83 PMID: 20359271
  42. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.
    Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20057-62 PMID: 19897719
  43. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.
    Cell Metab. 2008 Sep;8(3):249-56 PMID: 18762025
  44. Copper in the brain and Alzheimer's disease.
    J Biol Inorg Chem. 2010 Jan;15(1):61-76 PMID: 19862561
  45. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease.
    J Neurosci. 2008 Jun 18;28(25):6388-92 PMID: 18562609
  46. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10726-31 PMID: 15247418
  47. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma.
    J Neurosci Res. 2002 Feb 15;67(4):494-500 PMID: 11835316
  48. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.
    J Neurochem. 2009 Apr;109(2):502-12 PMID: 19200343
  49. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels.
    Bull Exp Biol Med. 2001 Nov;132(5):1079-83 PMID: 11865327
  50. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16505-10 PMID: 19805328
  51. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.
    J Mol Neurosci. 2010 May;41(1):110-3 PMID: 19834824
  52. Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.
    Prog Neurobiol. 2006 Jun;79(2):95-111 PMID: 16904810
  53. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition.
    Free Radic Biol Med. 2009 Oct 1;47(7):1019-27 PMID: 19596066
  54. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease.
    Free Radic Biol Med. 2008 Jun 15;44(12):2051-7 PMID: 18423383
  55. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain.
    Ann Neurol. 1983 Jan;13(1):72-8 PMID: 6219611
  56. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death.
    J Alzheimers Dis. 2010;21(2):389-402 PMID: 20555134
  57. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease.
    J Pharmacol Exp Ther. 2008 Jul;326(1):196-208 PMID: 18417733
  58. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies.
    J Alzheimers Dis. 2009;16(2):433-9 PMID: 19221432
  59. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease.
    FASEB J. 2009 Aug;23(8):2459-66 PMID: 19346295
  60. Neuroprotection through stimulation of mitochondrial antioxidant protein expression.
    J Alzheimers Dis. 2010;20 Suppl 2:S427-37 PMID: 20463397
  61. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease.
    Neurobiol Aging. 2012 Jan;33(1):197.e21-32 PMID: 20696495
  62. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators.
    Novartis Found Symp. 2007;287:60-3; discussion 63-9 PMID: 18074631
  63. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis.
    J Neurosci. 2009 Apr 1;29(13):4252-62 PMID: 19339619
  64. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.
    Acta Neuropathol. 2009 Jul;118(1):131-50 PMID: 19288120
  65. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
    J Neurosci. 2008 Sep 10;28(37):9287-96 PMID: 18784309
  66. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
    Mov Disord. 2010 Aug 15;25(11):1670-4 PMID: 20568096
  67. Mitochondrial accumulation of APP and Abeta: significance for Alzheimer disease pathogenesis.
    J Cell Mol Med. 2009 Oct;13(10):4137-45 PMID: 19725915
  68. Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
    Mol Psychiatry. 2006 Feb;11(2):172-81 PMID: 16331303
  69. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity.
    IUBMB Life. 2008 Jun;60(6):362-7 PMID: 18409172
  70. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.
    J Clin Psychopharmacol. 2008 Feb;28(1):110-3 PMID: 18204357
  71. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
    Arch Neurol. 2003 Dec;60(12):1685-91 PMID: 14676042
  72. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta.
    Biochim Biophys Acta. 2010 Jan;1802(1):198-204 PMID: 19616093
  73. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
    Int Clin Psychopharmacol. 2003 Mar;18(2):61-71 PMID: 12598816
  74. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies.
    Drugs Aging. 2010 Mar 1;27(3):181-92 PMID: 20210366
  75. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.
    CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8 PMID: 20205646
  76. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment.
    Ann Neurol. 2005 Nov;58(5):730-5 PMID: 16240347
  77. Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice.
    Neuroscience. 2004;128(1):73-89 PMID: 15450355
  78. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease.
    J Neurosci. 2009 Jul 15;29(28):9090-103 PMID: 19605646
  79. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.
    Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9926-30 PMID: 7937919
  80. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.
    J Alzheimers Dis. 2010;20 Suppl 2:S609-31 PMID: 20463406
  81. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.
    J Neurosci. 2008 Aug 13;28(33):8354-60 PMID: 18701698
  82. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
    J Biol Chem. 2003 Dec 19;278(51):50970-7 PMID: 14507922
  83. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.
    Arch Neurol. 2009 Mar;66(3):352-61 PMID: 19273754
  84. Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment.
    J Alzheimers Dis. 2010;21(4):1165-77 PMID: 21504121
  85. Oxidatively modified RNA in mild cognitive impairment.
    Neurobiol Dis. 2008 Feb;29(2):169-75 PMID: 17920285
  86. NADPH oxidase as a therapeutic target in Alzheimer's disease.
    BMC Neurosci. 2008 Dec 03;9 Suppl 2:S8 PMID: 19090996
  87. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
    Neuron. 2008 Jul 10;59(1):43-55 PMID: 18614028
  88. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein.
    Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1347-52 PMID: 18202172
  89. Evaluation of Dimebon in cellular model of Huntington's disease.
    Mol Neurodegener. 2008 Oct 21;3:15 PMID: 18939977
  90. Involvement of oxidative stress in Alzheimer disease.
    J Neuropathol Exp Neurol. 2006 Jul;65(7):631-41 PMID: 16825950
  91. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.
    PLoS One. 2009 Jun 01;4(6):e5757 PMID: 19484125
  92. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease.
    Neurobiol Dis. 2004 Mar;15(2):287-305 PMID: 15006699
  93. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.
    J Neurosci. 2006 May 10;26(19):5167-79 PMID: 16687508
  94. Scavenging of hypochlorous acid by lipoic acid.
    Biochem Pharmacol. 1991 Nov 6;42(11):2244-6 PMID: 1659823
  95. The neurobiology of isoprostanes and Alzheimer's disease.
    Biochim Biophys Acta. 2010 Aug;1801(8):930-3 PMID: 20116452
  96. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease.
    PLoS One. 2010 May 10;5(5):e10561 PMID: 20479943
  97. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease.
    J Neuroinflammation. 2006 Nov 09;3:30 PMID: 17094809
  98. Microglia in neurodegenerative disease.
    Nat Rev Neurol. 2010 Apr;6(4):193-201 PMID: 20234358
  99. Inactivation of nitric oxide synthases and cellular nitric oxide formation by N6-iminoethyl-L-lysine and N5-iminoethyl-L-ornithine.
    Eur J Pharmacol. 1998 Jun 5;350(2-3):325-34 PMID: 9696424
  100. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
    Behav Pharmacol. 2010 May;21(3):194-205 PMID: 20440202
  101. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
    Eur J Neurol. 2006 Jun;13(6):604-10 PMID: 16796584
  102. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress.
    Brain Res Bull. 1999 Sep 15;50(2):133-41 PMID: 10535332
  103. Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity.
    J Biol Chem. 2008 Nov 21;283(47):32176-87 PMID: 18815129
  104. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.
    Curr Alzheimer Res. 2010 Mar;7(2):97-112 PMID: 19939222
  105. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence.
    CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9 PMID: 20205647
  106. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction.
    Biochemistry. 1999 Jun 15;38(24):7609-16 PMID: 10386999
  107. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.
    J Neurochem. 2007 Aug;102(4):1095-104 PMID: 17472706
  108. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13576-81 PMID: 19666610
  109. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia.
    J Biol Chem. 2006 Jul 28;281(30):20842-20850 PMID: 16728400
  110. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration.
    J Alzheimers Dis. 2009;16(1):59-72 PMID: 19158422
  111. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques.
    J Neuropathol Exp Neurol. 1999 Nov;58(11):1163-9 PMID: 10560659
  112. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase.
    J Exp Med. 2005 Nov 7;202(9):1163-9 PMID: 16260491
  113. N-iminoethyl-L-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition.
    Neurochem Int. 2010 Jan;56(2):345-51 PMID: 19914323
  114. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways.
    J Neurochem. 2005 Feb;92(3):628-36 PMID: 15659232
  115. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.
    Nutr Res. 2009 Jan;29(1):70-4 PMID: 19185780
  116. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
    Cancer Res. 2005 Jun 1;65(11):4789-98 PMID: 15930299
  117. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
    Nature. 2006 Oct 19;443(7113):787-95 PMID: 17051205
  118. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia.
    J Biol Chem. 2005 Oct 28;280(43):35789-92 PMID: 16141213
  119. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice.
    J Neurochem. 2004 Jun;89(5):1308-12 PMID: 15147524
  120. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age.
    Free Radic Biol Med. 2008 Nov 15;45(10):1420-5 PMID: 18762245
  121. Animal and human studies with the mitochondria-targeted antioxidant MitoQ.
    Ann N Y Acad Sci. 2010 Jul;1201:96-103 PMID: 20649545
  122. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.
    CNS Neurosci Ther. 2008 Fall;14(3):215-26 PMID: 18801114
  123. Mitochondrial oxidative stress causes hyperphosphorylation of tau.
    PLoS One. 2007 Jun 20;2(6):e536 PMID: 17579710
  124. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.
    Neuroscience. 1998 Nov;87(2):319-24 PMID: 9740394
  125. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons.
    Eur J Pharmacol. 2008 Nov 12;597(1-3):51-6 PMID: 18801359
  126. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70 PMID: 18655815
  127. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L-carnitine.
    Neurochem Res. 2009 Apr;34(4):755-63 PMID: 18846423
  128. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Lancet. 2008 Jul 19;372(9634):207-15 PMID: 18640457
  129. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress.
    J Biol Chem. 2009 May 15;284(20):13291-5 PMID: 19182219
  130. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease.
    Neurology. 1996 Sep;47(3):705-11 PMID: 8797468
  131. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice.
    Free Radic Biol Med. 2010 Jan 1;48(1):161-72 PMID: 19854266
  132. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.
    J Biol Chem. 2007 Feb 16;282(7):4634-4642 PMID: 17178711
  133. Naturally occurring phytochemicals for the prevention of Alzheimer's disease.
    J Neurochem. 2010 Mar;112(6):1415-30 PMID: 20050972
  134. Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl)lysine.
    Biochemistry. 1998 Apr 7;37(14):4844-52 PMID: 9538001
  135. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.
    Mol Neurodegener. 2009 Dec 17;4:51 PMID: 20017949
  136. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology.
    Brain Res. 2001 Sep 14;913(1):57-67 PMID: 11532247
  137. The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation.
    J Bioenerg Biomembr. 2009 Oct;41(5):453-6 PMID: 19795195
  138. Causes of oxidative stress in Alzheimer disease.
    Cell Mol Life Sci. 2007 Sep;64(17):2202-10 PMID: 17605000
  139. Apocynin: molecular aptitudes.
    Mediators Inflamm. 2008;2008:106507 PMID: 19096513
  140. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid.
    Mol Cell Neurosci. 2008 Nov;39(3):302-13 PMID: 18706502
  141. The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration.
    Mol Neurobiol. 2005;31(1-3):43-63 PMID: 15953811
  142. Severe motor neuron degeneration in the spinal cord of the Tg2576 mouse model of Alzheimer disease.
    J Alzheimers Dis. 2010;21(1):263-76 PMID: 20421695
  143. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases.
    CNS Neurol Disord Drug Targets. 2007 Dec;6(6):411-23 PMID: 18220780
  144. Mitochondrial oxidative stress: implications for cell death.
    Annu Rev Pharmacol Toxicol. 2007;47:143-83 PMID: 17029566
  145. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.
    J Med Chem. 1994 Nov 11;37(23):3886-8 PMID: 7525961
  146. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis.
    J Neurochem. 2006 Aug;98(4):1141-8 PMID: 16895581
  147. Cytochrome c oxidase is decreased in Alzheimer's disease platelets.
    Neurobiol Aging. 2004 Jan;25(1):105-10 PMID: 14675736
  148. Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation.
    Ann Neurol. 1998 Oct;44(4):676-81 PMID: 9778267
  149. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease.
    FASEB J. 2004 Feb;18(2):323-5 PMID: 14656990
  150. Systemic inflammation and disease progression in Alzheimer disease.
    Neurology. 2009 Sep 8;73(10):768-74 PMID: 19738171
  151. DNA damage and repair in Alzheimer's disease.
    Curr Alzheimer Res. 2009 Feb;6(1):36-47 PMID: 19199873
  152. Dimebon as a potential therapy for Alzheimer's disease.
    CNS Spectr. 2009 Aug;14(8 Suppl 7):14-6; discussion 16-8 PMID: 19890242
  153. Systemic inflammatory cells fight off neurodegenerative disease.
    Nat Rev Neurol. 2010 Jul;6(7):405-10 PMID: 20531383
  154. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12867-72 PMID: 16908860
  155. [Effect of idebenone and various nootropic drugs on lipid peroxidation in rat brain homogenate in the presence of succinate].
    Nihon Yakurigaku Zasshi. 1988 May;91(5):295-9 PMID: 3410376
  156. Nitric oxide and nitroxidative stress in Alzheimer's disease.
    J Alzheimers Dis. 2007 May;11(2):207-18 PMID: 17522445
  157. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.
    J Neurosci. 2001 Nov 1;21(21):8370-7 PMID: 11606625
  158. Idebenone in senile dementia of Alzheimer type: a multicentre study.
    Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):249-60 PMID: 15374364
  159. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
    Neuropsychobiology. 1997;36(2):73-82 PMID: 9267856
  160. Transcriptional control of energy homeostasis through the PGC1 coactivators.
    Novartis Found Symp. 2007;286:3-6; discusssion 6-12, 162-3, 196-203 PMID: 18269170
  161. Vitamin E, antioxidant and nothing more.
    Free Radic Biol Med. 2007 Jul 1;43(1):4-15 PMID: 17561088
  162. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy.
    J Alzheimers Dis. 2010;19(1):355-61 PMID: 20061650
  163. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines.
    Biochem Pharmacol. 2005 Dec 5;70(12):1796-806 PMID: 16216225
  164. Oxidative damage is the earliest event in Alzheimer disease.
    J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67 PMID: 11487050
  165. Molecular mechanisms of Nrf2-mediated antioxidant response.
    Mol Carcinog. 2009 Feb;48(2):91-104 PMID: 18618599
  166. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
    Neurochem Res. 2010 Oct;35(10):1546-56 PMID: 20635141
  167. NOX activity is increased in mild cognitive impairment.
    Antioxid Redox Signal. 2010 Jun 15;12(12):1371-82 PMID: 19929442
  168. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.
    Gene Expr. 2002;10(5-6):271-8 PMID: 12450219
  169. Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation.
    Neuroscience. 2009 Jun 30;161(2):501-14 PMID: 19318118
  170. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.
    J Cell Mol Med. 2009 Feb;13(2):320-33 PMID: 18373733
  171. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
    Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8 PMID: 16286438
  172. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.
    Neurobiol Aging. 1995 Jan-Feb;16(1):1-4 PMID: 7723928
  173. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment.
    J Alzheimers Dis. 2010;19(1):363-72 PMID: 20061651
  174. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.
    J Neurosci. 2001 Jun 15;21(12):4183-7 PMID: 11404403
  175. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.
    Nat Neurosci. 2010 Apr;13(4):411-3 PMID: 20305648
  176. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.
    J Alzheimers Dis. 2008 Dec;15(4):571-87 PMID: 19096157
  177. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
    Arch Neurol. 2008 Jul;65(7):896-905 PMID: 18474729
  178. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Antioxid Redox Signal. 2009 Sep;11(9):2095-104 PMID: 19203217
  179. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
    Nat Rev Cancer. 2007 May;7(5):357-69 PMID: 17446857
  180. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.
    Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):267-81 PMID: 15975029
  181. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.
    BMC Pharmacol. 2010 Feb 05;10:2 PMID: 20137065
  182. Mitochondrial DNA mutations in disease, aging, and neurodegeneration.
    Ann N Y Acad Sci. 2008 Dec;1147:21-9 PMID: 19076427
  183. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease.
    Nucleic Acids Res. 2007;35(22):7497-504 PMID: 17947327
  184. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
    J Biol Chem. 2005 Feb 18;280(7):5892-901 PMID: 15590663
Article Info
Journal
Free radical biology & medicine
Abbr.
Free Radic Biol Med
ISSN
1873-4596
Published
2011-09-01
Epub
2010-00-01
Pages
1014-26
Language
English
Region
United States
NLM ID
8709159
PMCID
PMC3070183
Subset
IM
Grants
NIA NIH HHS · P01 AG014930-04 · United States
NIA NIH HHS · P01-AG14930 · United States
NIA NIH HHS · R01-AG20729 · United States
NIA NIH HHS · R01 AG020729-04 · United States
NIA NIH HHS · P01 AG014930 · United States
NIA NIH HHS · R01 AG020729 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com